In vivo protection of hematopoietic cells from alkylator-mediated DNA damage.

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Strategies that confer chemoresistance to hematopoietic stem and progenitor cells have two important future applications in the treatment of cancer and genetic diseases. Because dose-intensification of many cancer chemotherapy protocols is limited by severe hematopoietic toxicities, generation of primitive hematopoietic cells resistant to DNA damage mediated by chemotherapy may protect patients from life-threatening blood cytopenias. In addition, in the context of genetic diseases, overexpression of a chemoresistance gene in stem and progenitor cells may allow for the enrichment of small numbers of transduced cells that would not possess an in vivo selective advantage. In this report, I discuss studies that use the DNA repair protein O6-methylguanine DNA methyltransferase to protect hematopoietic cells from alkylator therapy. I focus on investigations evaluating the ability of O6-methylguanine-DNA methyltransferase mutant proteins to confer heightened resistance to alkylator-mediated DNA damage in vivo.

Original languageEnglish (US)
Pages (from-to)341-347
Number of pages7
JournalCurrent hematology reports
Volume2
Issue number4
StatePublished - Jul 2003

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this